BCM
BML Capital Management Portfolio holdings
AUM
$131M
1-Year Return
89.45%
This Quarter Return
-2%
1 Year Return
+89.45%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$108M
AUM Growth
-$2.72M
(-2.4%)
Cap. Flow
+$5.36M
Cap. Flow
% of AUM
4.94%
Top 10 Holdings %
Top 10 Hldgs %
89.99%
Holding
33
New
1
Increased
7
Reduced
6
Closed
7
Top Buys
| 1 |
iShares 0-3 Month Treasury Bond ETF
SGOV
|
$9.06M |
| 2 |
Atea Pharmaceuticals
AVIR
|
$7.69M |
| 3 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$5.77M |
| 4 |
CLYM
Climb Bio, Inc. Common Stock
CLYM
|
$934K |
| 5 |
VistaGen Therapeutics
VTGN
|
$524K |
Top Sells
| 1 |
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
|
$6.86M |
| 2 |
Abercrombie & Fitch
ANF
|
$4.43M |
| 3 |
Quince Therapeutics
QNCX
|
$2.12M |
| 4 |
Adverum Biotechnologies
ADVM
|
$1.86M |
| 5 |
Tilly's
TLYS
|
$1.34M |
Sector Composition
| 1 | Healthcare | 55.95% |
| 2 | Technology | 2.05% |
| 3 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Abercrombie & Fitch
ANF
$4.4B
| – | – |
-117,500
| Closed | -$4.43M |
|
27
Invivyd
IVVD
$203M
| – | – |
-134,696
| Closed | -$141K |
|
28
MEI Pharma
MEIP
$138M
| – | – |
-22,966
| Closed | -$151K |
|
|
29
Quince Therapeutics
QNCX
$85.9M
| – | – |
-1,411,839
| Closed | -$2.12M |
|
30
Invesco QQQ Trust
QQQ
$366B
| – | – |
0
| – | – |
|
|
31
Tilly's
TLYS
$60.3M
| – | – |
-190,518
| Closed | -$1.34M |
|
|
LENZ
32
LENZ Therapeutics
LENZ
$1.12B
| – | – |
-21,756
| Closed | -$396K |
|
|
PRDS
33
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| – | – |
-3,791,633
| Closed | -$6.86M |
|